# Octagon Capital Advisors LP

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1839435. Source: https://holderbook.com/funds/1839435-octagon-capital-advisors-lp/

- Reported value: $1.1B
- Positions: 27
- Weight of the ten largest: 78.5%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| DIANTHUS THERAPEUTICS INC | [DNTH](https://holderbook.com/stocks/DNTH/) | $179.5M | 1,841,667 | 16.1% | 12 |
| DEFINIUM THERAPEUTICS INC | [DFTX](https://holderbook.com/stocks/DFTX/) | $138.8M | 2,950,000 | 12.5% | 2 |
| ABIVAX SA | [ABVX](https://holderbook.com/stocks/ABVX/) | $132.3M | 993,000 | 11.9% | 6 |
| COGENT BIOSCIENCES INC | [COGT](https://holderbook.com/stocks/COGT/) | $90.9M | 2,350,000 | 8.2% | 8 |
| ALUMIS INC | [ALMS](https://holderbook.com/stocks/ALMS/) | $79.7M | 2,830,700 | 7.2% | 3 |
| ARRIVENT BIOPHARMA INC | [AVBP](https://holderbook.com/stocks/AVBP/) | $68.5M | 1,971,054 | 6.2% | 10 |
| TAYSHA GENE THERAPIES INC | [TSHA](https://holderbook.com/stocks/TSHA/) | $66.0M | 9,693,244 | 5.9% | 10 |
| BIOAGE LABS INC | [BIOA](https://holderbook.com/stocks/BIOA/) | $42.8M | 1,748,000 | 3.9% | 3 |
| MIRUM PHARMACEUTICALS INC | [MIRM](https://holderbook.com/stocks/MIRM/) | $39.7M | 338,900 | 3.6% | 2 |
| KYMERA THERAPEUTICS INC | [KYMR](https://holderbook.com/stocks/KYMR/) | $35.5M | 310,000 | 3.2% | 5 |
| AKTIS ONCOLOGY INC | [AKTS](https://holderbook.com/stocks/AKTS/) | $31.0M | 960,847 | 2.8% | 2 |
| XENON PHARMACEUTICALS INC | [XENE](https://holderbook.com/stocks/XENE/) | $29.6M | 490,000 | 2.7% | 2 |
| ERASCA INC | [ERAS](https://holderbook.com/stocks/ERAS/) | $23.0M | 0 | 2.1% | 1 |
| PALISADE BIO INC | [PALI](https://holderbook.com/stocks/PALI/) | $21.5M | 10,276,317 | 1.9% | 3 |
| OCULAR THERAPEUTIX INC | [OCUL](https://holderbook.com/stocks/OCUL/) | $20.4M | 2,075,000 | 1.8% | 10 |
| DISC MEDICINE INC | [IRON](https://holderbook.com/stocks/IRON/) | $19.7M | 270,000 | 1.8% | 2 |
| SUMMIT THERAPEUTICS INC | [SMMT](https://holderbook.com/stocks/SMMT/) | $18.2M | 1,250,000 | 1.6% | 1 |
| PHARVARIS N V | [PHVS](https://holderbook.com/stocks/PHVS/) | $15.8M | 456,721 | 1.4% | 8 |
| ADLAI NORTYE LTD | [ANL](https://holderbook.com/stocks/ANL/) | $10.7M | 934,716 | 1.0% | 1 |
| PRECISION BIOSCIENCES INC | [DTIL](https://holderbook.com/stocks/DTIL/) | $10.6M | 1,350,000 | 1.0% | 3 |
| DBV TECHNOLOGIES S A | [DBVT](https://holderbook.com/stocks/DBVT/) | $9.4M | 574,200 | 0.8% | 5 |
| FAETH THERAPEUTICS INC | [FTH](https://holderbook.com/stocks/FTH/) | $9.0M | 361,010 | 0.8% | 1 |
| GYRE THERAPEUTICS INC | [GYRE](https://holderbook.com/stocks/GYRE/) | $6.3M | 954,416 | 0.6% | 1 |
| TREVI THERAPEUTICS INC | [TRVI](https://holderbook.com/stocks/TRVI/) | $5.9M | 315,000 | 0.5% | 6 |
| UNICYCIVE THERAPEUTICS INC | [UNCY](https://holderbook.com/stocks/UNCY/) | $4.7M | 1,000,000 | 0.4% | 5 |
| CONTEXT THERAPEUTICS INC | [CNTX](https://holderbook.com/stocks/CNTX/) | $1.7M | 3,050,000 | 0.2% | 2 |
| GOSSAMER BIO INC | [GOSS](https://holderbook.com/stocks/GOSS/) | $1.3M | 7,750,000 | 0.1% | 23 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +27.7% | +14.8% | +12.9% | 90% |
| Q1 2026 | +11.7% | -4.6% | +16.3% | 91% |
| Q4 2025 | +36.9% | +2.4% | +34.5% | 97% |
| Q3 2025 | +65.3% | +7.8% | +57.5% | 99% |
| Q2 2025 | +9.5% | +10.5% | -1.0% | 88% |
| Q1 2025 | -17.8% | -4.6% | -13.3% | 96% |
| Q4 2024 | -2.3% | +2.1% | -4.5% | 97% |
| Q3 2024 | +5.3% | +5.4% | -0.1% | 94% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $1.1B | 27 |
| Q1 2026 | $903.6M | 29 |
| Q4 2025 | $823.7M | 27 |
| Q3 2025 | $659.8M | 26 |
| Q2 2025 | $455.6M | 30 |
| Q1 2025 | $516.8M | 34 |
| Q4 2024 | $607.7M | 31 |
| Q3 2024 | $642.9M | 41 |
| Q2 2024 | $636.3M | 44 |
| Q1 2024 | $834.4M | 56 |
| Q4 2023 | $625.0M | 33 |
| Q3 2023 | $650.9M | 37 |